Functional somatic syndrome: how it could be relevant to rheumatologists

References

• Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999;354(9182):936–9.
   Google Scholar
• Barsky A, Borus J. Functional somatic syndrome. Ann Intern Med 1999;130:910–21.
   PubMed Web of Science ®Google Scholar
• Sharpe M, Carson A. "Unexplained" somatic symptoms, func-tional syndromes, and somatization: do we need a paradigm shift? Ann Intern Med 2001;134(9 Pt 2):926–30.
   Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:1143–7.
   Google Scholar
• Van Houdenhove B, Egle UT. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychother Psycho-som 2004;73(5):267–75.
   PubMed Web of Science ®Google Scholar
• Scott A, Mihailidou A, Smith R, Kellow J, Jones M, Lorang C, et al. Functional gastrointestinal disorders in unselected patients with non-cardiac chest pain. Scand J Gastroenterol 1993;28(7): 585–90.
   PubMed Web of Science ®Google Scholar
• Meeus M, Nijs J, Meirleir KD. Chronic musculoskeletal pain in patients with the chronic fatigue syndrome: a systematic review. Eur J Pain 2006;11:377–386.
   Google Scholar
• Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121(12):953–9.
   PubMed Web of Science ®Google Scholar
• Crofford LJ. The hypothalamic-pituitary-adrenal stress axis in fi-bromyalgia and chronic fatigue syndrome. Z Ftheumatol 1998;57 Suppl 2:67–71.
   Google Scholar
• Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci 1998;840:684–97.
   PubMed Web of Science ®Google Scholar
• Neeck G, Crofford LJ. Neuroendocrine perturbations in fibro-myalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000;26(4):989–1002.
   PubMed Web of Science ®Google Scholar
• Gaab J, Huster D, Peisen R, Engert V, Heitz V, Schad T, et al. Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and phar-macological stimulation. Psychosom Med 2002;64(6):951–62.
   PubMed Web of Science ®Google Scholar
• Bradley LA, McKendree-Smith NL, Alarcon GS. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain 2000;4(2):148–57.
   PubMedGoogle Scholar
• Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syn-drome. Lancet 2006;367(9507):346–55.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Skowera A, Cleare A, Wessely S. Chronic fatigue syn-drome: an update focusing on phenomenology and pathophysiol-ogy. Curr Opin Psychiatry 2006;19(1):67–73.
   PubMed Web of Science ®Google Scholar
• Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001; 31(8):1331–45.
   Google Scholar
• Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003;24(2):236–52.
   PubMed Web of Science ®Google Scholar
• Inder WJ, Prickett TC, Mulder RT. Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clin Endocrinol (Oxf) 2005;62(3):343–8.
   Google Scholar
• Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Normal hypo-thalamo-pituitary-adrenal axis function in a rat model of periph-eral neuropathic pain. Brain Res 2005;1044(2):216–26.
   Google Scholar
• Veale D, Kavanagh G, Fielding JF, Fitzgerald 0. Primary fibro-myalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br J Ftheumatol 1991;30(3): 220–2.
   Google Scholar
• Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006;6:26.
   Google Scholar
• Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999;94(12):3541–6.
   Google Scholar
• Whitehead WE, Palsson 0, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122 (4): 1140–56.
   Google Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130(5):1377–90.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Iovino P, Tremolaterra F, Parsons WJ, Ciacci C, Maz-zacca G. Fibromyalgia in patients with irritable bowel syndrome: an association with the severity of the intestinal disorder. Int J Colorectal Dis 2001;16(4):211–5.
   Google Scholar
• Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93(1):7–14.
   Google Scholar
• Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Ftheumatol Rep 2002; 4(4):322–8.
   PubMedGoogle Scholar
• Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, et al. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003; 103(1,2):99–110.
   Google Scholar
• Price DD, Zhou Q, Moshiree B, Robinson ME, Nicholas Verne G. Peripheral and central contributions to hyperalgesia in irritable bowel syndrome. J Pain 2006;7(8):529–35.
   Google Scholar
• Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Nali-boff B, et al. Brain responses to visceral and somatic stimuli in pa-tients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003;98(6):1354–61.
   Google Scholar
• Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gas-troenterology 1987;93(4):727–33.
   PubMedGoogle Scholar
• Iovino P, Tremolaterra F, Consalvo D, Sabbatini F, Mazzacca G, Ciacci C. Perception of electrocutaneous stimuli in irritable bowel syndrome. Am J Gastroenterol 2006;101(3):596–603.
   PubMedGoogle Scholar
• Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 Pt 1):1187–92.
   Google Scholar
• Ness TJ, Powell-Boone T, Cannon R, Lloyd LK, Fillingim RB. Psychophysical evidence of hypersensitivity in subjects with inter-stitial cystitis. J Urol 2005;173(6):1983–7.
   PubMedGoogle Scholar
• Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006;8(3):208.
   PubMedGoogle Scholar
• Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromy-algia syndrome. Nat Chin Pract Ftheumatol 2006;2(2):90–8.
   PubMedGoogle Scholar
• Bell IR, Baldwin CM, Schwartz GE. Sensitization studies in chemi-cally intolerant individuals: implications for individual difference research. Ann N Y Acad Sci 2001;933:38–47.
   Google Scholar
• Nijs J, Meeus M, De Meirleir K. Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications. Man Ther 2006;11(3):187–91.
   Google Scholar
• Stander S, Schmelz M. Chronic itch and pain: similarities and dif-ferences. Eur J Pain 2006;10(5):473–8.
   PubMed Web of Science ®Google Scholar
• Schaible HG, Ebersberger A, Von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci 2002;966:343–54.
   PubMed Web of Science ®Google Scholar
• Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Ana1g 2003;97(4):1108–16.
   Google Scholar
• Henriksson KG, Sorensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):343–51.
   PubMedGoogle Scholar
• Wood PB. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 2006;7(9): 611–4.
   PubMedGoogle Scholar
• Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004;65 Suppl 12:16–9.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67(8):1219–25.
   PubMed Web of Science ®Google Scholar
• Kato K, Sullivan PF, Evengard B, Pedersen Nt. Chronic wide-spread pain and its comorbidities: a population-based study. Arch Intern Med 2006;166(15):1649–54.
   PubMedGoogle Scholar
• Stahl SM. Does depression hurt? J Clin Psychiatry 2002;63(4): 273–4.
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ftibeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibro-myalgia. J Ftheumatol 2005;32(10):1975–85.
   Google Scholar
• Gormsen L, Ftibe AR, Raun P, Rosenberg R, Videbech P, Vester-gaard P, et al. Pain thresholds during and after treatment of severe depression with electroconvulsive therapy. Eur J Pain 2004;8(5): 487–93.
   Google Scholar
• Usui C, Doi N, Nishioka M, Komatsu H, Yamamoto R, Ohkubo T, et al. Electroconvulsive therapy improves severe pain associated with fibromyalgia. Pain 2006;121(3):276–80
   PubMed Web of Science ®Google Scholar
• Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52(5):1577–84.
   PubMed Web of Science ®Google Scholar
• Boucher W, el-Mansoury M, Pang X, Sant GR, Theoharides TC. Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Br J Urol 1995;76(1):94–100.
   Google Scholar
• Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theoharides TC. Mast cell and substance P-positive nerve involvement in a pa-tient with both irritable bowel syndrome and interstitial cystitis. Urology 1996;47(3):436–8.
   Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gas-troenterology 2004;126(3):693–702.
   PubMed Web of Science ®Google Scholar
• Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, et al. Diarrhoea-predominant IBS patients show mast cell activa-tion and hyperplasia in the jejunum. Gut 2006;56:203–209.
   PubMedGoogle Scholar
• Wood J. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut 2006;55:445–447.
   PubMedGoogle Scholar
• La JH, Kim TW, Sung TS, Kim HJ, Kim JY, Yang IS. Role of mucosa' mast cells in visceral hypersensitivity in a rat model of ir-ritable bowel syndrome. J Vet Sci 2004;5(4):319–24.
   PubMedGoogle Scholar
• Zuo Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hy-peralgesia induced by nerve injury in the rat: a key role of mast cells. Pain 2003;105(3):467–79.
   PubMed Web of Science ®Google Scholar
• Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 1996;314 (Pt 41009–16.
   Google Scholar
• Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Pro-teinase-activated receptors. Pharmacol Rev 2001;53(2):245–82.
   Google Scholar
• Kawabata A, Kawao N, Kuroda R, Tanaka A, Itoh H, Nishikawa H. Peripheral PAR-2 triggers thermal hyperalgesia and nocicep-tive responses in rats. Neuroreport 2001;12(4):715–9.
   PubMedGoogle Scholar
• Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 2001;7(7):821–6.
   PubMed Web of Science ®Google Scholar
• Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyp eralgesia in rats. Gastroenterology 2002;122(4): 1035–47.
   Google Scholar
• Bueno L. Gastrointestinal pharmacology: irritable bowel syn-drome. Curr Opin Pharmacol 2005;5(6):583–8.
   PubMedGoogle Scholar
• Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Func-tional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006;18(1):6–17.
   PubMed Web of Science ®Google Scholar
• Kawao N, Ikeda H, Kitano T, Kuroda R, Sekiguchi F, Kataoka K, et al. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci 2004;94(3):277–85.
   PubMedGoogle Scholar
• Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007. Feb 15 [Epub ahead of print].
   Google Scholar
• Ding-Pfennigdorff D, Averbeck B, Michaelis M. Stimulation of PAR-2 excites and sensitizes rat cutaneous C-nociceptors to heat. Neuroreport 2004;15(13):2071–5.
   Google Scholar
• Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnol-le N, et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006;126(4):746–55.
   Google Scholar
• Enestrom S, Bengtsson A, Frodin T. Dermal IgG deposits and in-crease of mast cells in patients with fibromyalgia-relevant findings or epiphenomena? Scand J Ftheumatol 1997;26(4):308–13.
   Google Scholar
• Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, et al. Detection of interleukin lbeta (IL-lbeta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Ftheu-matol 2003;30(1):146–50.
   Google Scholar
• Santos J, Saperas E, Nogueiras C, Mourelle M, Antolin M, Cadahia A, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998;114(4): 640–8.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Papaliodis D, Tagen M, Konstantinidou A, Kempuraj D, Clemons A. Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol 2005;25(6): 515–20.
   PubMedGoogle Scholar